BioChimPharm, the founding member of the Georgian Bio Pharmaceutical cluster, has completed EUR 6 million modernization project at the historic phage manufacturing facility in Tbilisi, which dates back to 1934. BioChimPharm is now producing life-saving, phage-based novel antibiotics with European precision and quality.
„We would like to express our heartfelt appreciation to our dear local and international partners (European Union, EBRD, Enterprise Georgia, FAO, ProCredit Bank and GITA) without whom this project would not have been possible. To honor their contributions, we proudly introduce the PHAGE AWARD, recognizing their outstanding commitment to fighting antimicrobial resistance and advancing Phage Technology.
In today’s focus, we highlight the EBRD! We extend our sincere gratitude to the European Bank for Reconstruction and Development, the EBRD Georgia team, and EBRD Regional Director, Catarina Bjorlin Hansen, for their remarkable support in the fight against AMR and the development of Phage Technology.
Please join us in celebrating this achievement by viewing the photos from our prize-giving ceremony, which showcase the dedication of our partners. Together, we are making significant strides in combating AMR and propelling Phage Technology. “ – Rati Golijashvili, General Manager of JSC Biochimpharm.